Loading...
•
Jun 30, 2020
Cardiff Oncology Q2 2020 Earnings Report
Announced second quarter 2020 results and company highlights.
Key Takeaways
Cardiff Oncology reported its second quarter 2020 results, highlighting clinical advancements in KRAS-mutated metastatic colorectal cancer and acute myeloid leukemia programs, along with securing $25.1 million in equity investments, warrant exercises, and clinical trial funding commitments.
Presented data demonstrating efficacy of onvansertib in combination with standard-of-care therapy in KRAS-mutated metastatic colorectal cancer.
Announced positive efficacy and safety results of Phase 1b trial in relapsed/refractory acute myeloid leukemia.
Advanced Phase 2 trial in metastatic castrate-resistant prostate cancer.
Secured financing of $25 million from equity investments, warrant exercises, and clinical study commitments.
Forward Guidance
Cardiff Oncology did not provide specific forward guidance in this earnings report.
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...